Guangdong Medpark's Two Portfolio Companies, Weichun Biotech and Tiankeya BioPharma, Named as Guangzhou 'Future Unicorns' and File IPO Prospectus

The selection of the "Future Unicorn" list of innovative companies has strict criteria and is an authoritative recognition of a company's innovation capability, market prospects, and industry influence. The listed companies have meticulously cultivated their respective niche fields, mastered core technologies, and demonstrated excellent growth potential, serving as the backbone of Guangzhou's innovative strength.

As high-quality enterprises introduced by MEDV, the two companies have made remarkable achievements through continuous efforts in their niche fields:Guangdong TCRCure Biopharma Technology Co., Ltd.Focus on the innovation, development, and clinical translation of cellular immunotherapy in the treatment of solid tumors. Relying on several self-developed cell engineering platform technologies, eight R&D pipelines are currently underway to explore the application prospects of immune cell therapy across various cancer types.

Weichun Biotechnology (Guangzhou) Co., Ltd.One of the few manufacturers globally that fully masters the preparation technology of high-pressure liquid chromatography silica gel fillers and resin fillers. The team has over 20 years of industry experience, accumulating extensive expertise in product applications and method development. Possessing a complete industrial chain from raw material monomer production of silica gel and resin microspheres to internationally leading surface bonding modification processes, analytical chromatography columns/semi-preparative columns, and preparative filler production, providing high-quality, cost-effective, stable supply, and fast delivery products and services for pharmaceutical manufacturing, biotechnology, food safety, chemical production, environmental testing, and other industries.

The selection of these two enterprises this time is inseparable from the empowerment and support of MEDV's full-chain industrial ecosystem, which integrates "industrial cluster × industrial services × industrial investment," and serves as another strong testament to the cultivation achievements of MEDV's industrial ecosystem. At MEDV, we assist enterprises in solving financing difficulties, help them accurately connect with innovative resources, and create diversified platforms for exchange and cooperation. To date, MEDV has cumulatively nurtured 4 listed companies, 47 high-tech enterprises, 26 specialized and new small and medium-sized enterprises, 3 specialized and new "little giant" enterprises, and 5 future unicorn enterprises.

In the future, MEDV will continue to deepen its presence in the biopharmaceutical field, constantly improve its industrial ecosystem layout, optimize service systems, gather more innovative resources, and help more high-quality enterprises join the ranks of unicorns. It aims to promote the high-quality development of the biopharmaceutical industry in the Greater Bay Area and steadily advance towards the goal of building a world-class biopharmaceutical industry cluster!

Congratulations again to Weichun Biotechnology (Guangzhou) Co., Ltd. and Guangdong TCRCure Biopharma Technology Co., Ltd.!

We look forward to more park enterprises seizing the opportunity and creating further brilliance!